onc Videos

Videos

Conference Coverage

Asciminib Continues to Demonstrate Efficacy and Tolerability Among Patients With CML in Chronic Phase

01/10/2024

Featuring David Andorsky, MD

At the 65th ASH Annual Meeting, David Andorsky, MD, discussed an interim analysis of the AIM4CML trial, which indicated that asciminib treatment continued to demonstrate efficacy and tolerability among patients with CML chronic phase.

At the 65th ASH Annual Meeting,...

01/10/2024

Oncology

Conference Coverage

Examining Efficacy of Frontline Bendamustine-Rituximab and Second-Line BTK Inhibitor Therapy Among Patients With MCL

01/10/2024

Featuring Yucai Wang, MD, PhD

At the 65th ASH Annual Meeting, Yucai Wang, MD, PhD, discusses trial findings that first-line bendamustine-rituximab and second-line Bruton’s tyrosine kinase inhibitor therapy yielded efficacious outcomes among patients with mantle cell...

At the 65th ASH Annual Meeting,...

01/10/2024

Oncology

Conference Coverage

Recent Breakthroughs in the Mantle Cell Lymphoma Treatment Landscape

01/08/2024

Featuring Bijal D. Shah, MD

Bijal D. Shah, MD, shares the breakthroughs in the mantle cell lymphoma treatment landscape that he found most promising at the 65th American Society of Hematology (ASH) Annual Meeting.

Bijal D. Shah, MD, shares the...

01/08/2024

Oncology

Conference Coverage

Genomic Driven Artificial Intelligence Based System to Detect and Diagnose Lobular Carcinoma

01/05/2024

Featuring Fresia Pareja, MD, PhD

Featuring Fresia Pareja, MD, PhD ...

Fresia Pareja, MD, PhD, discussed novel mechanisms of CDH1 inactivation discovered using an artificial intelligence based system.

Fresia Pareja, MD, PhD,...

01/05/2024

Oncology

Conference Coverage

Use of Quantitative Multiplex Immunofluorescence Assay to Detect TROP2 and HER2 Expression

01/05/2024

Featuring David Rimm, MD, PhD

David Rimm, MD, PhD, discussed study results which identified quantitative multiplex immunofluorescence assay as an optimal way to detect TROP2 and HER2 expression in breast cancer.

David Rimm, MD, PhD, discussed...

01/05/2024

Oncology

Robert Rifkin, MD, Rocky Mountain Cancer Centers

Conference Coverage

Analyzing Outpatient Administration and Step-Up Dosing of Teclistamab Among Patients With Multiple Myeloma

01/05/2024

Featuring Robert M. Rifkin, MD

Featuring Robert M. Rifkin, MD ...

At the 65th American Society of Hematology Annual Meeting in San Diego, California, Robert M Rifkin, MD, discusses a study analyzing the outpatient administration of step-up doses of BCMA-targeting bispecific antibody teclistamab.

At the 65th American Society of...

01/05/2024

Oncology

Conference Coverage

Demographic, Germline Genetic Findings From Patients in Puerto Rico Based on Personal/Family History of Breast Cancer

01/04/2024

Featuring Hannah Cox, PhD, HCLD

Featuring Hannah Cox, PhD, HCLD ...

Hannah Cox, PhD, HCLD, discussed clinical findings from genetic analyses of Puerto Rican patients with a personal/family history of breast cancer.

Hannah Cox, PhD, HCLD, discussed...

01/04/2024

Oncology

Conference Coverage

Use of Fertility Preservation and Assisted Reproductive Technologies to Attempt Pregnancy Among Patients With Breast Cancer

01/04/2024

Featuring Hatem Azim, MD, PhD

Hatem Azim, MD, PhD, discussed results from the POSITIVE trial.

Hatem Azim, MD, PhD, discussed...

01/04/2024

Oncology

Conference Coverage

Vepdegestrant Plus Palbociclib for Patients With ER-Positive, HER2-Negative Advanced Breast Cancer

01/04/2024

Featuring Seth Wander, MD, PhD

Featuring Seth Wander, MD, PhD ...

Seth Wander, MD, PhD, discussed results from the phase 1b cohort of a phase 1/2 clinical trial, demonstrating that vepdegestrant plus palbociclib is clinically effective among patients with heavily pretreated, ER-positive, HER2-negative...

Seth Wander, MD, PhD, discussed...

01/04/2024

Oncology

Conference Coverage

ctDNA Monitoring of Patients With ER-Positive, HER2-Negative High Risk Breast Cancer During Adjuvant Endocrine Therapy

01/03/2024

Featuring Lajos Pusztai, MD, DPhil

Featuring Lajos Pusztai, MD, DPhil ...

Lajos Pusztai, MD, DPhil, discussed results from the DARE study which analyzed the clinical utility of ctDNA monitoring during adjuvant endocrine therapy to detect molecular relapse before apparent recurrence.

Lajos Pusztai, MD, DPhil,...

01/03/2024

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology